RxDoctor Payments Data

Ashley Peden, NP

Family · Jackson, MSNPI 1104597947

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 51 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$272
  • Novo Nordisk$259
  • Takeda Pharmaceuticals U.S.A., Inc.$76
  • Genentech USA, Inc.$67
  • Sanofi-aventis U.S. LLC$67
  • Lilly USA, LLC$63
  • plus $345 from 12 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,149 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$50,744
Medicare patients
383
Services billed
1,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$57,199
MounjaroTirzepatide44$46,352
WegovySemaglutide12$18,460
Cefdinir28$543
Ipratropium Bromide18$449
Doxycycline Hyclate50$300
Azithromycin61$275
Fluticasone Propionate26$200
Methylprednisolone31$194
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$178
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$136
Ciprofloxacin Hcl28$122
Ondansetron OdtOndansetron14$122
Levofloxacin18$112
Losartan Potassium18$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$259$75,65971 claims
Lilly USA, LLCMounjaro$63$46,35244 claims
PfizerPaxlovid$24$012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →